Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nuvo/Mallinckrodt’s Pennsaid Setback Starts Clock On Generic Launch

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

With Nuvo’s new Pennsaid 2% formulation hung up at FDA, Apotex may be able to launch its generic of the old 1.5% formulation of the topical diclofenac product on April 1, 2014, under a settlement announced in January.

You may also be interested in...

Nuvo/Galderma Face More Manufacturing Woes Over Topical Anesthetic

Galderma pulled Pliaglis from the market in 2008 over manufacturing issues, which the specialty pharma thought were resolved when it submitted an sNDA last fall. Regulators, however, still have questions surrounding the daub on, peel off product’s manufacture, which has now been transferred from a third-party to Galderma.

Covidien Pure-Play: Pharma Spin-Off Now Officially In The Works

Covidien says it has been working for several years towards separating out its pharma business from its larger and more profitable devices/supplies division.

Nuvo's Pennsaid “Approvable” For Osteoarthritis

Company plans to meet with FDA in early 2007 to discuss the topical non-steroidal anti-inflammatory treatment.


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts